The April 2026 federal cannabis rescheduling order may become one of the most important legal developments for cannabis M&A in years. But for anyone looking to buy, sell, finance, broker, or invest in a cannabis business, the most important takeaway is also the most practical one:
There are still more questions than answers.
The order does not legalize cannabis nationwide. It does not fully reschedule all cannabis activity. It does not automatically eliminate every federal risk for cannabis companies. And it does not mean that a California cannabis business should suddenly be valued, diligenced, or structured like an ordinary non-cannabis business.
Instead, the order creates a new and uncertain legal landscape where the details matter. In particular, buyers and sellers should be looking closely at whether the business is medical, adult-use, or both; whether the business may qualify for Schedule III treatment; whether DEA registration is required or strategically advisable; how Section 280E may apply; and whether the transaction should be structured as an asset purchase, equity purchase, merger, or other transaction.
For California cannabis businesses, the analysis may be especially complicated because California is both a medical and adult-use cannabis market. That means a buyer may be looking at a business that operates under medical designations, adult-use designations, or both. That distinction may now matter more than it did before.
This article explains how the April 2026 rescheduling order may affect cannabis M&A, especially for buyers and sellers of California cannabis businesses.
What Did the April 2026 Cannabis Rescheduling Order Do?
At a high level, the April 2026 order moved state medical marijuana and FDA-approved prodcuts to Schedule III of the federal Controlled Substances Act.
That is a narrower result than full cannabis legalization or full rescheduling of every cannabis business in the country. Adult-use cannabis, unlicensed cannabis, and cannabis activity outside the scope of a qualifying medical marijuana license may remain subject to Schedule I treatment unless and until broader federal action is completed.
For buyers and sellers, this distinction matters. A cannabis company’s value, tax profile, compliance obligations, financing options, and deal structure may depend on whether the business is operating in a medical-only market, an adult-use market, or a mixed medical/adult-use market.
Why This Matters for Cannabis M&A
Buying or selling a cannabis business has always required industry-specific diligence. Cannabis deals involve state licensing, local approvals, ownership restrictions, track-and-trace compliance, tax exposure, vendor issues, real estate limitations, financing constraints, and federal illegality concerns.
The rescheduling order does not eliminate those issues. It may add a new layer.
After the order, a cannabis M&A diligence review should not only ask whether the business is licensed under state law. It should also ask:
- Is the license medical, adult-use, or both?
- Are the products or operations covered by the federal order? How?
- Has the business applied for or obtained DEA registration?
- Is DEA registration mandatory, optional, or strategically advisable for this business?
- How does the business separate medical and adult-use activity?
- How are revenues, expenses, inventory, employees, facilities, and records allocated between medical and adult-use operations?
- Does the company have a defensible position on Section 280E?
- Has the seller made aggressive tax assumptions that the buyer could inherit?
- Should the transaction be structured to isolate historical liabilities?
These questions should be addressed before the parties sign a letter of intent, not after the purchase agreement is already being negotiated.
Medical-Only States vs. California’s Medical and Adult-Use Market
California has both medicinal and adult-use cannabis activity, and many operators participate in both sides of the market. That creates a harder diligence question: which part of the business is medical, which part is adult-use, and how cleanly can the two be separated?
For example, a California retailer may sell to both medical patients and adult-use customers. A manufacturer may produce products that enter both medical and adult-use channels. A distributor may handle inventory destined for different categories of licensed operators. A vertically integrated business may have cultivation, manufacturing, distribution, and retail operations that are not cleanly separated for accounting, inventory, or operational purposes.
In that type of deal, a buyer should not simply ask, “Is this a licensed cannabis company?” The better questions are:
- Which licenses are medical, adult-use, or both?
- Which revenue streams are medical vs. adult-use?
- Which expenses support medical operations, adult-use operations, or both?
- How is inventory tracked between medical and adult-use channels?
- Are medical and adult-use products segregated in the company’s records?
- Do the company’s tax returns reflect any allocation between medical and adult-use activity?
- Has the seller changed its license designation or business model in response to rescheduling?
- Would the buyer need to preserve the seller’s medical designation to maintain the expected tax or regulatory position?
In California cannabis deals, buyers should expect this to become a major diligence issue.
DEA Registration May Become a Key Deal Issue
One of the biggest unresolved questions is the role of DEA registration.
The order creates a federal registration pathway for state-licensed medical marijuana entities. That pathway may allow certain state medical marijuana licensees to seek registration as manufacturers, distributors, or dispensers under federal law.
But for M&A purposes, the issue is not simply whether a seller can apply for DEA registration. The issue is how the existence, absence, timing, scope, or transferability of that registration affects the transaction.
Buyers should ask:
- Has the seller applied for DEA registration?
- Was the application timely?
- What category of registration was sought?
- Is the registration tied to a specific state license, facility, activity, or entity?
- Does the registration automatically suspend if the state license is suspended, revoked, transferred, or expires?
- Can the buyer rely on the seller’s pending application?
- Will a change of ownership, asset transfer, merger, or equity sale trigger a new DEA registration requirement?
- Does the transaction require DEA notice, approval, amendment, or a new application?
- If the seller does not have DEA registration, is that a closing condition, post-closing covenant, indemnity issue, or valuation adjustment?
These questions may be especially important in California, where state and local cannabis licenses can already be difficult to transfer or restructure. If federal registration tracks the state license, then any issue with the state license may become a federal issue as well.
Section 280E and Cannabis Valuation
Section 280E has historically been one of the most important tax issues in cannabis. In general, Section 280E disallows ordinary business deductions for businesses trafficking in Schedule I or Schedule II controlled substances.
If certain state-licensed medical marijuana activity is now treated as Schedule III, then medical cannabis operators may have a stronger argument that Section 280E should not apply to those qualifying activities. Treasury and IRS guidance is expected to be critical, especially for businesses with both medical and adult-use operations.
For cannabis M&A, the practical issue is valuation.
A seller may argue that the business is now more valuable because its future tax burden may be lower. A buyer may respond that the tax benefit is uncertain, especially where the company operates in both medical and adult-use channels or has not clearly allocated expenses.
That can affect:
- EBITDA adjustments;
- Quality of earnings analysis;
- Working capital calculations;
- Purchase price;
- Earnouts;
- Tax indemnities;
- Escrow amounts;
- Representations and warranties;
- Closing conditions;
- Disclosure schedules.
A seller should be careful not to overstate the tax benefit. A buyer should be careful not to price the deal based on tax assumptions that may not survive future IRS guidance, audit scrutiny, or changes in the business model.
Asset Sale vs. Equity Sale After Rescheduling
The rescheduling order does not mean that every cannabis acquisition should be structured the same way. Deal structure still matters.
In cannabis M&A, buyers often consider asset purchases because they may help isolate certain historical liabilities. But asset sales in cannabis can be complicated because licenses, permits, leases, local approvals, inventory, and vendor relationships are not typically freely assignable.
Equity sales may preserve continuity of licenses and operations (assuming they’re handled compliantly), but they may also expose the buyer to historical liabilities, including tax liabilities, regulatory violations, employment claims, unpaid vendors, debt, litigation, and ownership disclosure issues.
After rescheduling, the asset sale vs. equity sale question may become even more fact-specific. For example:
- If a DEA registration is tied to the entity, an equity acquisition may preserve continuity more easily than an asset sale. However, research into the transferability of the registration should be done.
- If the seller has unresolved tax exposure, an asset purchase may be more attractive to the buyer
- If the seller has mixed medical and adult-use operations, the parties may need to isolate assets, liabilities, contracts, inventory, and revenues by category.
- If the buyer wants the benefit of medical-only operations, the parties need to determine whether the transaction structure preserves that status.
The main point is that deal structure should be considered at the outset. It should not be treated as a purely tax-driven or lawyer-driven issue after business terms are already agreed.
Due Diligence Issues for Buyers
A buyer considering a California cannabis business should expand its diligence checklist after rescheduling. In addition to ordinary cannabis diligence, the buyer should investigate whether the business can support the legal and tax assumptions driving the deal.
Key diligence categories include:
1. License Diligence
Review all state and local licenses, permits, approvals, renewals, notices of violation, ownership disclosures, premises approvals, and license designations. Determine whether each license is medical, adult-use, or both.
2. DEA Registration Diligence
Determine whether the seller has applied for DEA registration, obtained registration, or made a deliberate decision not to apply. Review the scope of any registration and whether it may be affected by a change in ownership or control.
3. Medical vs. Adult-Use Allocation
Review how the company separates medical and adult-use revenue, expenses, inventory, customers, products, and compliance records. If the seller cannot show clean allocation, the buyer should be cautious about relying on medical-only tax or regulatory assumptions.
4. Tax Diligence
Review historical tax returns, Section 280E positions, cost of goods sold methodology, amended returns, protective claims, correspondence with tax authorities, and any post-rescheduling tax planning.
5. Financial Diligence
Analyze whether the company’s stated profitability depends on assumed 280E relief, unpaid taxes, non-recurring adjustments, related-party expenses, or optimistic post-rescheduling projections.
6. Compliance Diligence
Review track-and-trace records, product testing, packaging, labeling, inventory reconciliation, waste disposal, recalls, advertising, ownership disclosures, and regulatory correspondence.
7. Contracts and Liabilities
Review leases, management agreements, supply agreements, distribution agreements, debt documents, investor agreements, broker agreements, employment matters, litigation, and any change-of-control restrictions.
8. Deal Structure Diligence
Evaluate whether an asset purchase, equity purchase, or other structure best preserves licensing, minimizes liability, and supports the buyer’s federal and state compliance strategy.
Issues Sellers Should Address Before Going to Market
Sellers should not wait for buyer diligence to identify problems. A seller preparing to market a cannabis business should organize the company’s records and develop a defensible story around rescheduling.
Before going to market, sellers should consider:
- Confirming license designations and local approvals;
- Separating medical and adult-use records where possible;
- Reviewing whether DEA registration is required or advisable;
- Working with tax counsel and accountants on Section 280E assumptions;
- Cleaning up ownership disclosures and financial interest holder records;
- Resolving outstanding notices of violation or compliance issues;
- Preparing clear financial statements;
- Documenting any post-rescheduling tax assumptions;
- Reviewing leases and contracts for change-of-control restrictions;
- Deciding whether an asset sale or equity sale is more realistic.
A seller that can clearly explain its medical vs. adult-use operations, tax assumptions, DEA registration strategy, and compliance history may be better positioned to defend valuation and move through diligence efficiently.
How Brokers, Investors, and Attorneys Should Think About Cannabis Deals Now
The April 2026 order also affects professionals around the transaction.
Brokers
Brokers should be cautious about marketing a cannabis business as “Schedule III” without understanding whether the business is medical, adult-use, or both. Marketing materials should avoid overstating tax benefits or implying that federal legalization has occurred.
Investors
Investors should evaluate whether a target’s valuation is based on actual legal changes, expected future guidance, or speculation. Medical-only operators may be affected differently than adult-use operators or mixed operators.
Attorneys
Attorneys should raise rescheduling issues early in the LOI stage. The purchase agreement may need specific representations, covenants, indemnities, closing conditions, and tax provisions addressing medical licensing, DEA registration, 280E, adult-use activity, and post-closing compliance.
Practical M&A Checklist After Cannabis Rescheduling
Anyone buying or selling a cannabis business should consider the following checklist:
- Identify every state and local license.
- Confirm whether each license is medical, adult-use, or both.
- Review whether the business may qualify as state-licensed medical marijuana activity.
- Determine whether DEA registration is required, available, pending, or obtained.
- Analyze whether DEA registration would survive the proposed deal structure.
- Separate medical and adult-use revenue where possible.
- Separate medical and adult-use expenses where possible.
- Review historical Section 280E positions.
- Review any amended returns, refund claims, or protective tax filings.
- Confirm whether the purchase price assumes 280E relief.
- Evaluate whether the transaction should be structured as an asset sale or equity sale.
- Review state and local change-of-ownership rules.
- Review leases, debt, vendor contracts, and investor agreements.
- Confirm whether any approvals are required before closing.
- Build tax and regulatory uncertainty into the purchase agreement.
Frequently Asked Questions
Does the April 2026 rescheduling order make it easier to buy a cannabis business?
Possibly, but not automatically. The order may improve the legal and tax profile of certain state-licensed medical cannabis businesses, but it does not fully legalize or reschedule all cannabis activity. Buyers still need detailed diligence on licensing, tax, DEA registration, medical vs. adult-use activity, and transaction structure.
Does rescheduling eliminate Section 280E for cannabis businesses?
Not for every cannabis business. Section 280E applies to businesses trafficking in Schedule I or II controlled substances. If a business is engaged only in qualifying Schedule III medical marijuana activity, it may have a stronger argument for ordinary business deductions. But mixed medical/adult-use businesses may need to allocate expenses, and further Treasury/IRS guidance is expected.
Is California cannabis now Schedule III?
Not necessarily. California has both medical and adult-use cannabis. The April 2026 order only covers marijuana subject to a state medical marijuana license and FDA-approved products, not all adult-use cannabis activity. A California business may need to analyze its specific licenses, products, customers, and operations.
Do California cannabis companies need DEA registration?
This may become one of the most important questions after rescheduling. The order creates a DEA registration pathway for state-licensed medical marijuana entities, but the practical consequences may depend on the license type, business activity, timing of application, deal structure, and future agency guidance. Buyers and sellers should analyze this before signing an LOI.
Should a cannabis acquisition be structured as an asset sale or equity sale after rescheduling?
It depends. An asset sale may help isolate historical liabilities, but it may create license transfer, DEA registration, and operational continuity issues. An equity sale may preserve licenses and registrations more easily, but it may also expose the buyer to historical tax, regulatory, and contractual liabilities. The structure should be considered at the beginning of the deal.
What should sellers do before marketing a cannabis business?
Sellers should organize license records, confirm medical and adult-use designations, review tax positions, evaluate DEA registration issues, clean up compliance records, prepare financial statements, and work with counsel before going to market. A seller that can answer diligence questions clearly may be better positioned to attract serious buyers.
Talk to a Cannabis M&A Attorney Before Signing an LOI
The April 2026 rescheduling order may create new opportunities in cannabis M&A, but it also creates new uncertainty. Buyers and sellers should not wait until the purchase agreement stage to analyze medical vs. adult-use licensing, DEA registration, Section 280E, valuation, or deal structure.
If you are considering buying, selling, investing in, or brokering a California cannabis business, schedule a free consultation before signing a letter of intent.
A focused legal review at the beginning of the deal can help identify risks, preserve leverage, and structure the transaction around the issues that matter most.
